Step by step towards an animal-free laboratory: marine algae extracts as key to sustainable laboratory reagents
Bremerhaven, October 2026
Whether in medical diagnostics or biomedical research, antibodies and DNA-based detection methods form the foundation of modern diagnostics and biomedical research. The use of protein solutions is essential for the production of these components and for maintaining their stability and specificity. Under current industry standards, these critical properties are ensured by animal-derived supplements such as bovine serum albumin (BSA) and foetal calf serum (FCS), which are obtained under ethically controversial conditions. This approach is now virtually incompatible with today’s demands for ethical and resource-conserving laboratory practice.
Through a joint research project, ZytoVision GmbH (a company of the Zytomics Group) and Bremerhaven University of Applied Sciences aim to provide groundbreaking impetus for the development of serum-free biotechnological solutions, thereby combining innovative biotechnology with sustainable production approaches. The focus is on using functional algal extracts to completely replace BSA in antibody stabilisation and as a blocking solution in DNA hybridisation. To this end, commercial monoclonal antibodies are mixed with algal protein extracts and their stability is tested in immunohistochemical and in situ hybridisation systems. If successful, the project has the potential to significantly reduce the use of animal sera as stabilisers and blocking reagents in the medium term, and ultimately to replace them entirely with commercial algal extracts. This project also complements the “Green mAK” project, which is likewise funded by the BIS; the aim of the latter is to produce “green antibodies” for the first time and to demonstrate their suitability for use in medical diagnostics.
On the part of ZytoVision GmbH, the research project is scientifically led by Marcus Gräber-Gerberding, Vice President of Research and Development at the Zytomics Group, and Dr Britta Meyer, Senior Scientific R&D Project Coordinator at ZytoVision GmbH.
The project is funded by BIS Bremerhaven and co-financed by the European Union under the European Regional Development Fund (ERDF Bremen 2021–2027).
Dr Sandra Götze, Scientific Project Coordinator, ZytoVision GmbH, Fischkai 1, 27572 Bremerhaven,
Tel.: 0471 / 4832 341, www.zytomics.com
Selecting your region and language ensures you receive the corresponding product portfolio and contact details.